Headlines about Accuray (NASDAQ:ARAY) have trended somewhat positive this week, Accern reports. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Accuray earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned press coverage about the medical equipment provider an impact score of 46.3231275990774 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the news stories that may have effected Accern’s scoring:
- Coming Out Of Shadows? Entravision Communications Corporation (EVC), Accuray Incorporated (ARAY) – Market Movers (financialqz.com)
- Accuray Incorporated (ARAY) Expected to Post Quarterly Sales of $91.29 Million (americanbankingnews.com)
- Horizon Pharma Public Limited Company (HZNP) has a value of $13.42 per share While Accuray Incorporated (ARAY … – Stocks Gallery (stocksgallery.com)
- Analysts Anticipate Accuray Incorporated (ARAY) to Post -$0.10 Earnings Per Share (americanbankingnews.com)
Accuray (ARAY) opened at $4.80 on Friday. Accuray has a 1-year low of $3.60 and a 1-year high of $6.00. The company has a quick ratio of 0.92, a current ratio of 1.48 and a debt-to-equity ratio of 2.44.
A number of brokerages have recently commented on ARAY. Jefferies Group LLC reiterated a “buy” rating and issued a $7.00 target price on shares of Accuray in a report on Wednesday, August 9th. Royal Bank Of Canada reiterated a “hold” rating and issued a $5.00 target price on shares of Accuray in a report on Thursday, August 24th. BTIG Research reiterated a “hold” rating on shares of Accuray in a report on Thursday, August 24th. Zacks Investment Research upgraded Accuray from a “sell” rating to a “hold” rating in a report on Tuesday, September 19th. Finally, BidaskClub cut Accuray from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company’s stock. Accuray has a consensus rating of “Hold” and a consensus price target of $6.29.
In related news, COO Kelly Londy sold 99,136 shares of the business’s stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $4.24, for a total transaction of $420,336.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.90% of the stock is owned by insiders.
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.
Receive News & Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.